Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It's lead clinical program's drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II clinical trial of icovamenib for treating insulin-deficient type 2 diabetes; and COVALENT-212, which is in Phase II clinical trial of icovamenib for the treatment of type 2 diabetes. The company is also developing BMF-650, which is in Phase I glucagon-like peptide-131 clinical trial for the treatment of obesity. The company was incorporated in 2017 and is headquartered in San Carlos, California.…
Biomea Fusion to Participate in Upcoming Investor Conferences
Biomea Fusion (NASDAQ: BMEA) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 34 employees.
The shares were at 0.5744 USD on 20 November 2026, down 58.1% over 52 weeks. Its 52-week range is 0.4502 USD to 2.237 USD: the price is 74.3% below the high and 27.6% above the low.
Its market capitalisation is 41.75M USD.
Biomea Fusion reports return on equity of -209.1% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 25.90M USD. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. The next earnings report is expected on 23 March 2027.